Ltr Pharma
- Short interest
- 0.08%
- −0.01 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 146.7K
- Shares on issue
- 182.275M
Ltr Pharma (LTP) Short Interest
Ltr Pharma (ASX:LTP) had 0.08% of shares reported as short positions as of 8 Oct 2026, representing 146,719 shares. Ltr Pharma operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Ltr Pharma
LTR Pharma is an Australian drug development company focused on men's health, specifically commercializing a rapid-onset, on-demand therapeutic nasal spray for erectile dysfunction. Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, aiming for faster action and improved spontaneity compared to existing ED therapies.
Company profile →Ltr Pharma (ASX:LTP) has 0.08% of its shares on issue reported as short positions as of 8 Oct 2026, or about 146,719 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.53% in July 2024. LTP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads LTP today
- Zanger BreakoutWatchScore 25rank 960 of 1942
- CAN SLIMWatchScore 25rank 438 of 1541
- Minervini Trend TemplateWatchScore 18rank 987 of 1716
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 10rank 1233 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
LTP fundamentals
In the year to 30 Jun 2026, Ltr Pharma (ASX:LTP) recorded revenue of A$1.6M and a net loss after tax of A$14.2M. A year earlier it recorded revenue of A$145.8K and a net loss after tax of A$5.6M. Net margin −874.1% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest LTP news
All news- Investor Webinar Presentation
asx · 5 Oct 2026
- First ROXUS Prescriptions Fulfilled in the United States
asx · 5 Oct 2026
- LTR Pharma (ASX:LTP) Gains 5% as SPONTAN Data Builds the Regulatory Picture - Kalkine
googlenews · 5 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss LTP
Start a research thread or post the first pulse update